Eligard three-month injectable
This article was originally published in Pharmaceutical Approvals Monthly
Three-month sustained-release Eligard (leuprolide acetate for injectable suspension) 22.5 mg receives FDA approval July 24 for the palliative treatment of advanced prostate cancer. Once-monthly 7.5 mg Eligard was approved Jan. 23 and launched in May. Physicians often start patients on a monthly leuprolide formulation and then switch responding patients to a 90- or 120-day product (Pharmaceutical Approvals Monthly, February 2002, p. 3
You may also be interested in...
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far.